Insight
Pierre Blanchard
centerforurologiccare.com

Perioperative Durvalumab with Neoadjuvant Chemotherapy in Bladder Cancer

Yakup Ergün, Medical Oncologist at Bower Hospital, shared a post on X:

“Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer.

NIAGARA trial

Event Free Survival and Overall Survival.

Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer

Authors: Thomas Powles,  James W.F. Catto, Matthew D. Galsky, Hikmat Al-Ahmadie, Joshua J. Meeks, Hiroyuki Nishiyama, Toan Quang Vu, Lorenzo Antonuzzo, Pawel Wiechno, Vagif Atduev, Ariel G. Kann, Tae-Hwan Kim, Cristina Suárez, Chao-Hsiang Chang, Florian Roghmann, Mustafa Özgüroğlu, Bernhard J. Eigl, Niara Oliveira, Tomas Buchler, Moran Gadot, Yousef Zakharia, Jon Armstrong, Ashok Gupta, Stephan Hois, Michiel S. van der Heijden.”

Perioperative Durvalumab with Neoadjuvant Chemotherapy in Bladder Cancer

Perioperative Durvalumab with Neoadjuvant Chemotherapy in Bladder Cancer

 

Ariel G. Kann Ashok Gupta Bernhard J. Eigl bladder cancer cancer Chao-Hsiang Chang Cristina Suárez event-free survival Florian Roghmann Hikmat Al-Ahmadie Hiroyuki Nishiyama James W.F. Catto Jon Armstrong Joshua J. Meeks Lorenzo Antonuzzo Matthew D. Galsky Michiel S. Van der Heijden Moran Gadot Mustafa Özgüroğlu Neoadjuvant chemotherapy (NACT) Niara Oliveira OncoDaily Oncology overall survival Pawel Wiechno Perioperative Durvalumab Stephan Hois Tae-Hwan Kim Thomas Powles Toan Quang Vu Tomas Buchler Vagif Atduev Yakup Ergün Yousef Zakharia